BJH - volume 15, issue 8, december 2024
R. van der Voort PhD
SUMMARY
Teclistamab is registered as a monotherapy in patients with relapsed or refractory multiple myeloma after previous ‘triple-class’ therapy. Recently, results from the MajesTEC-1 trial showed that teclistamab was safe and effective not only in patients who received ‘triple-class’ therapy in the past, but also for those who received both ‘triple-class’ therapy and BCMA-targeted therapy.
(BELG J HEMATOL 2024;15(8):315–7)
Read more
Top
